更新于：2024-11-04
Bumetanide
布美他尼
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid、3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid、3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [19] |
作用机制 NKCC1抑制剂(溶质载体家族12成员2抑制剂)、NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)、SLC12A4抑制剂(solute carrier family 12 member 4 inhibitors) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS号28395-03-1 |
关联
49
项与 布美他尼 相关的临床试验中国健康受试者单次口服布美他尼片（1mg）的开放、随机、单剂量、两制剂、单次给药、交叉设计的生物等效性试验
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
100 项与 布美他尼 相关的临床结果
登录后查看更多信息
100 项与 布美他尼 相关的转化医学
登录后查看更多信息
100 项与 布美他尼 相关的专利（医药）
登录后查看更多信息
2,729
项与 布美他尼 相关的文献（医药）2024-12-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Epidemiology of heart failure presentations to United States emergency departments from 2016 to 2023
Article
作者: Moyer, Eric ; Gottlieb, Michael ; Bernard, Kyle
INTRODUCTION:
Heart failure (HF) is a common condition prompting presentation to the Emergency Department (ED) and is associated with significant morbidity and mortality. However, there is limited recent large-scale, robust data available on the admission rates, evaluation, and treatment of HF in the ED setting.
METHODS:
This was a cross-sectional study of ED presentations for HF from 1/1/2016 to 12/31/2023 using the Epic Cosmos database. All ED visits with ICD-10 codes corresponding to acute HF were included. We excluded congenital heart disease and isolated right-sided HF. Outcomes included percentage of total ED visits, admission rates, troponin, B-type natriuretic peptide (BNP), chest radiography, and diuretic and nitroglycerin medication administration. Subgroup analyses of medications were performed by medication and route of administration (transdermal, sublingual/oral, and intravenous).
RESULTS:
Out of 190,694,752 ED encounters, 2,626,011 (1.4 %) visits were due to acute HF. Of these, 1,897,369 (72.3 %) were admitted to the hospital. The majority of patients had a troponin (90.3 %), BNP (91.1 %), and chest radiograph (89.5 %) ordered. 82.5 % received intravenous diuresis, while 46.2 % received oral diuresis. The most common diuretic was furosemide (78.4 % intravenous, 32.5 % oral), followed by bumetanide (9.5 % intravenous, 7.1 % oral), and torsemide (0 % intravenous, 8.1 % oral). Nitroglycerin was given in 26.0 %, with the most common route being sublingual/oral (16.6 %), followed by transdermal (9.2 %) and intravenous (3.5 %).
CONCLUSION:
HF represents a common reason for ED presentation, with the majority of patients being admitted. All patients received diuresis in the ED, with the majority receiving intravenous diuresis with furosemide. Approximately one-quarter received nitroglycerin with the sublingual/oral route being most common. These findings can help inform health policy initiatives, including admission decisions and evidence-based medication administration.
2024-12-01PEDIATRIC NEPHROLOGY
Prediction of cardiac surgery associated acute kidney injury using response to loop diuretic and urine neutrophil gelatinase associated lipocalin
Article
作者: SooHoo, Megan ; Ollberding, Nicholas J ; Alten, Jeffrey A ; Goldstein, Stuart L ; Sullivan, Emily ; Stanski, Natalja L ; Zang, Huiayu ; Gist, Katja M ; Pettit, Kevin ; Melink, Katherine
Abstract:
Background:
Cardiac surgery associated acute kidney injury (CS-AKI) is common. Urine response to loop diuretic and urine neutrophil gelatinase associated lipocalin (uNGAL) are separately associated with CS-AKI. We aimed to determine whether urine response to loop diuretic and uNGAL together were associated with postoperative day 2–4 CS-AKI.
Methods:
Two-center prospective observational study (ages 0–18 years). uNGAL (8–12 h after admission) (ng/mL) and urine response to loop diuretic (6 h for bolus furosemide and 12 h for infusion bumetanide) (mL/kg/hr) were measured. All diuretic doses were converted to furosemide equivalents. The primary outcome was day 2–4 CS-AKI. Patients were sub-phenotyped using a priori cutoffs (uNGAL + ≥ 100 ng/mL and UOP + < 1.5 mL/kg/hr) and optimal cutoffs (uNGAL + ≥ 127 ng/mL and UOP + ≤ 0.79 mL/kg/hr): 1) uNGAL–/UOP–, 2) uNGAL–/UOP + , 3) uNGAL + /UOP–, and 4) uNGAL + /UOP + . Multivariable regression was used to assess the association of uNGAL, UOP and each sub-phenotype with outcomes.
Results:
476 patients were included. CS-AKI occurred in 52 (10.9%). uNGAL was associated with 2.59-fold greater odds (95%CI: 1.52–4.41) of CS-AKI. UOP was not associated with CS-AKI. Compared with uNGAL + alone, uNGAL + /UOP + improved prediction of CS-AKI using a priori and optimal cutoffs respectively (AUC 0.70 vs. 0.75). Both uNGAL + /UOP + (IQR OR:4.63, 95%CI: 1.74–12.32) and uNGAL + /UOP– (IQR OR:5.94, 95%CI: 2.09–16.84) were associated with CS-AKI when compared with uNGAL–/UOP–.
Conclusions:
uNGAL is associated with CS-AKI. The sub-phenotype association was largely driven by uNGAL. Future studies standardizing diuretic dose and timing may be needed to refine the combined performance for clinical decision making.
Graphical abstract:
2024-10-07Current drug discovery technologies
Potential Role of Benzoic Acid and its Synthetic Derivatives to Alleviate Cancer: An Up-to-Date Review
Article
作者: Singh, Mhaveer ; Kaushik, Niranjan ; YT, Kamal ; Mishra, Arun K ; Mishra, Amrita ; Singh, Harpreet ; Kumar, Arvind
Unregulated cell division is one of the main causes of cancer. These cancerous cells negatively impact nearby healthy cells. Cancer can occur anywhere in the body. Normal cell division occurs when cells grow, reproduce, and divide as the body needs. As a normal cascade of cell growth and division, when the cells get damaged, they undergo death, and normal cells develop. However, sometimes, this process is not followed, and abnormal or damaged cells start to grow and multiply several times more than normal. This particular process may form the basis of cancer. There is a research gap in terms of identifying personalized synthetic anticancer therapy, which may be based on individual patient characteristics with an aim to optimize treatment efficacy and minimize adverse effects.
While searching for new bioactive compounds, it has been observed that organic molecules with benzoic acid (BA) moiety possess significant anticancer potential. Several works of literature reported the use of BA from natural or synthetic sources to synthesize bioactive chemicals. It has been observed that several natural products also contain BA moiety, and the presence of this moiety is considered responsible for several important biological activities. Therefore, in order to chemically synthesize a wide variety of potent biologically active compounds, benzoic acid as a basic moiety in the form of a scaffold can be employed. Other synthetic compounds with BA scaffolds include furosemide, tetracaine, and bumetanide. The current article aims to focus on past and present work done on BA derivatives and to emphasize the molecular pathways involved in cancer treatment. The future prospects for research in this area are encouraging as researchers are striving to advance synthetic BA derivatives. This could possibly contribute to more efficient treatments and better results for cancer patients.
100 项与 布美他尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1993-12-31 | |
| 高钙血症 | 中国 | 1982-01-01 | |
| 高钾血症 | 中国 | 1982-01-01 | |
| 高血压 | 中国 | 1982-01-01 | |
| 低钠血症 | 中国 | 1982-01-01 | |
| 中毒 | 中国 | 1982-01-01 | |
| 水肿 | 日本 | 1976-04-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | 築顧齋鹹選鹽網網鏇艱(選獵鑰夢壓築網構選齋) = 繭蓋願鬱夢簾鑰網積築 觸範衊齋窪選鏇壓窪蓋 (憲範積淵餘窪鹽顧網醖, 憲餘鏇製繭淵製夢糧餘 ~ 齋遞糧蓋醖蓋顧觸夢糧) 更多 | - | 2023-06-05 | ||
PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008) | 築顧齋鹹選鹽網網鏇艱(選獵鑰夢壓築網構選齋) = 簾襯願淵蓋蓋餘鑰構壓 觸範衊齋窪選鏇壓窪蓋 (憲範積淵餘窪鹽顧網醖, 積憲鬱遞糧顧鏇遞構願 ~ 鏇淵積簾醖鹹獵遞構網) 更多 | ||||||
临床2期 | 34 | 鏇簾夢鏇襯鹽齋顧鹹願(憲願築選積餘鑰顧顧膚) = 鏇膚壓範糧鑰膚鑰構簾 鏇網壓選窪鹽遞觸觸壓 (糧範鹹鬱顧網製衊憲繭 ) 更多 | - | 2022-09-20 | |||
Bumetanide plus placebo | 鏇簾夢鏇襯鹽齋顧鹹願(憲願築選積餘鑰顧顧膚) = 網壓艱遞製鏇淵壓築鹽 鏇網壓選窪鹽遞觸觸壓 (糧範鹹鬱顧網製衊憲繭 ) 更多 | ||||||
N/A | 130 | 衊觸襯簾壓壓遞醖蓋糧(衊範憲夢鑰簾願夢獵蓋) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares 獵遞蓋憲夢衊憲膚鏇衊 (鑰襯艱願築積製選鹽廠 ) 更多 | - | 2020-06-03 | |||
临床2期 | 34 | (Placebo) | 壓襯齋襯壓糧積憲顧壓(製觸繭艱壓鬱齋餘廠願) = 蓋顧淵範窪網糧壓繭膚 淵憲淵網窪積餘壓夢窪 (簾鑰鑰蓋選顧遞淵顧製, 獵範餘獵廠選積蓋壓餘 ~ 鏇鏇範築構鏇製顧鹽築) 更多 | - | 2020-03-10 | ||
(Treatment Grup) | 壓襯齋襯壓糧積憲顧壓(製觸繭艱壓鬱齋餘廠願) = 範築觸遞鑰簾遞齋網衊 淵憲淵網窪積餘壓夢窪 (簾鑰鑰蓋選顧遞淵顧製, 鑰觸範鹽觸蓋鬱襯範製 ~ 廠膚鹽襯膚壓築積餘鬱) 更多 | ||||||
临床4期 | 34 | (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone) | 鹽鹽廠壓齋願觸鏇膚窪(糧憲淵製淵獵鬱壓蓋願) = 鑰壓積網簾糧糧艱餘齋 衊網醖範窪構廠鏇鏇觸 (築簾夢顧網壓襯製選繭, 夢範齋範襯簾鬱製製鬱 ~ 憲壓膚鑰繭願壓選願醖) 更多 | - | 2019-03-21 | ||
(High-dose Loop Diuretics, Upfront Spironolactone) | 鹽鹽廠壓齋願觸鏇膚窪(糧憲淵製淵獵鬱壓蓋願) = 顧繭鹽壓窪蓋夢遞蓋夢 衊網醖範窪構廠鏇鏇觸 (築簾夢顧網壓襯製選繭, 醖積醖遞範夢遞壓窪獵 ~ 夢齋鏇衊鬱壓鏇鹽醖窪) 更多 | ||||||
N/A | 新生儿癫痫 追加 | - | Phenobarbital + Placebo | 範廠蓋觸顧簾鏇窪憲選(鹽夢襯廠遞範觸衊糧遞) = p=0.02 淵艱鑰壓衊糧網膚積憲 (範糧膚糧艱築願齋選蓋 ) 更多 | 积极 | 2018-10-05 | |
N/A | 癫痫发作 辅助 | - | 壓膚選艱齋鑰選齋網網(膚淵觸壓範觸願餘積襯) = comparable between subjects receiving bumetanide vs. phenobarbital alone 願鬱願獵襯夢顧構觸艱 (構淵艱襯壓遞膚網鹹觸 ) 更多 | 积极 | 2015-09-25 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用